ReviewSmall science2026
Emerging Biomedical Engineering Therapies for Infected Diabetic Foot Ulcers: Toward Antibacterial Functionalization and Pathology-Responsive Regulation.
Review in Small science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infected diabetic foot ulcer (DFU) endangers patients through complex complications, which seriously increase the risk of amputation, prolongation of disability time and mortality, as well as bring a heavy burden to the medical system. This review focuses on the emerging biomedical engineering therapy of DFU and deeply analyzes the multiple pathogenic factors driving these intractable DFU wounds, including impaired angiogenesis, inflammatory disorder, microbial biofilm formation, and impaired immune response. It also synthesizes current clinical treatments and elaborates on their limitations that underscore the need for innovative solutions. The core of the review delves into recent breakthroughs in responsive antimicrobial biomaterials, emphasizing their stimuli-triggered mechanisms that enable targeted drug release, enhanced bacterial eradication, and tissue regeneration promotion. Furthermore, it explores future trajectories for multifunctional biomaterials, envisioning integrated systems that combine antimicrobial, anti-inflammatory, and pro-healing properties to address the complex pathophysiology of infected DFU. By bridging current clinical challenges with biomaterial innovations, it can provide actionable insights for developing patient-centric therapeutic strategies in biomedical engineering.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.